3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Hepatitis B
4
Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma
1
Liver Failure, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Fibrosis
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
Rituximab
193
Cyclophosphamide
177
fludarabine phosphate
151
Peripheral Blood Stem Cell Transplantation
89
fludarabine
77
Mycophenolic Acid
70
Filgrastim
63
Whole-Body Irradiation
59
Tacrolimus
55
Lenalidomide
54
Cyclosporine
54
ibrutinib
53
Bendamustine Hydrochloride
50
Busulfan
49
Melphalan
45
Radiotherapy
42
Etoposide
42
Alemtuzumab
42
Antilymphocyte Serum
40
ofatumumab
35
obinutuzumab
33
Methotrexate
33
venetoclax
27
Cytarabine
25
sargramostim
23
Granulocyte Colony-Stimulating Factor
22
Dexamethasone
21
Methylprednisolone
19
Bortezomib
19
Chlorambucil
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
Lamivudine
×
Clear all
NCT03528941
2022-05-12
LLC1618
Gruppo Italiano Malattie EMatologiche dell'Adulto
Completed
109 enrolled